Replies to post #166990 on Amarin Corp Plc (AMRN)

[Jt0082]

AGREED bfost, lots of impatient fishes out there who are good at timing things within 1 second of predicated announcements based on chart movements lol :)

On the ITC matter well covered by Sonam/oneragman: This seems to be a jurisdictional case. Obviously AMRN testing the law around two big regulatory organisations (ITC/FDA). These things are no small matter as it would set major precedent. It is understandable this is taking more time than usual. Its a very big decision with big ramifications not only for Amarin. My personal view is there will be some communication between FDA and ITC behind closed doors and that in order for the FDA not to lose face or their jurisdictional precedence.. they might come out with some sort of policy where dietary supplements should not be used to treat medical conditions. That is, some policy restricting the amount of pure EPA dietary supplements on the market or the labels of dietary supplements (similar to the 2 recent lawsuits) or the max % amount of EPA in each pill where it crosses over from a DS to a medical product. Well I guess that's my personal hope (could be wrong) and that's why I agree with some others on here that chastising the FDA (BB) about the history of ANCHOR is really not such a bright idea.

One thing nobody has mentioned on here (very surprising) and I think would be a MAJOR positive for shareholders is a V price increase. We all know JT has said its a volume gain, but its obvious we got something good and there is going to be a lot of demand for V over the next few years. The data was so good, so much better than more expensive PCSK9s and I think the pharma-economic studies to come over next few months are going to give Amarin a great opportunity for a nice price increase next year. Supply VS Demand tells me doing this right now is a no-brainer.

ahhhhhh SAM, we all miss you today :)

PS watching week to week scripts is fun but I am only expecting scripts to really take off around Feb/March.

[FlyFishingStocks]

Bfost - I owned stock in EXAS. I agree, there are similarities to AMRN. Here is a more detailed chart of EXAS.

I think AMRN may follow a similar path to EXAS. Exas got USPSTF approval for it's cologuard product in July 2016, then dropped after a big pop, then went sideways for about 6-9 months before starting it's upward climb.

I totally agree.

I think patience will pay off in a big way with a similar chart.

Agree again... kind of. We find ourselves in a much different situation post reduce-it when it comes to volume trades. Dollar volume has gone up 532%. This minimizes slippage (bid-ask spread) and makes it very easy to dance in and out of a position if one were to decide to sides step the dips. It's not hard to spot the turning points,... the slope of the 50dEMA guides the way. With that in mind, "Patience" = less pay off and more painful loss along the way (notice how the binary gap filled - yikes).
Anyway, the 50% retrace is the line in the sand IMO. Based on the drug efficacy, we should all end up richer from a similar chart outcome and more, but there will be growing doubts during any painful retrace over the next few months.

[NickHous]

I agree bfost, just looks like patience will pay off extremely well! We are in that awkward stage right now. Need to get through our awkward adolescence age, pop a few zits and then get laid finally! Oh yeah, I'm waiting for that ultimate goal of getting laid "feeling" when it all pays off! Now there is something I can get behind! HaHa! GLTA

[VuBru]

Bfost - I agree about the impatience. Having heard recent comments from a large private pharma I consult with that "we can't do that until next budget year," it makes me wonder whether the unexpected positive nature of R-It results may mean that no BP was prepared with budget resources for a BO quickly. Maybe they are as we speak factoring in possible BO money into next year's budget so that an offer can be made in Q1 2019 as HDG expects. We shall see.